CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
外周血嗜酸性粒细胞计数对接受 CAR-T 细胞治疗的弥漫大 B 细胞淋巴瘤患者预后的影响
英文原题：Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
查看英文原题
Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
对于对 CAR-T 细胞治疗有反应的患者，嗜酸性粒细胞计数也可用于预测 6 个月的缓解持续时间。总之，CAR-T 治疗后的嗜酸性粒细胞计数与接受 CAR-T 细胞治疗患者的预后相关，并可用于临床识别在 CAR-T 细胞输注后能够实现更长缓解的患者。
研究思路结论见上方概要
背景
嵌合抗原受体（CAR）T细胞疗法是复发/难治性弥漫大B细胞淋巴瘤患者的突破性治疗。然而，许多患者未能达到缓解或缓解后复发。既往研究表明，嗜酸性粒细胞与CD8+ T细胞具有协同抗肿瘤作用，且CAR-T 细胞治疗前嗜酸性粒细胞计数与CAR-T 细胞的疗效相关。
方法
我们回顾性分析了弥漫性大B细胞淋巴瘤患者的嗜酸性粒细胞计数，发现其在CAR-T 细胞治疗前后发生了显著变化。
结果
接受CAR-T 细胞输注后达到完全缓解的患者，其CAR-T 后嗜酸性粒细胞计数高于未达到完全缓解的患者。Kaplan-Meier曲线显示，CAR-T 细胞输注后第二个月嗜酸性粒细胞计数较高的患者，其无进展生存期和总生存期优于嗜酸性粒细胞计数较低的患者。
展开英文摘要原文
METHODS
We retrospectively analyzed the eosinophil counts of patients with diffuse large B-cell lymphoma and found it changed remarkably pre- and post-CAR T-cell therapy.
RESULTS
Patients who achieved complete remission after CAR T-cell infusion had greater post-CAR T-eosinophil counts than those who did not. Kaplan-Meier curves showed that patients with greater eosinophil counts during the second month after CAR T-cell infusion had superior progression-free survival and overall survival compared with those with lower eosinophil counts.
CONCLUSIONS
For patients who responded to CAR T-cell therapy, eosinophil counts also can be used to predict 6-month duration of response. In conclusion, the post-CAR T-eosinophil count is associated with the prognosis of patients treated with CAR T-cell therapy and can be used to clinically identify patients who can achieve longer remission after CAR T-cell infusion.
论文信息
- 作者
- Dang X、Ye S、Zhou L、Lu Y、Li P、Liang A、Qian W
- 第一作者单位
- Department of Hematology, Shanghai Tongji Hospital, Shanghai, China.China
- 通讯作者单位
- Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Electronic address: qianwb@zju.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cytotherapy2023 Jun
- 原文标识
- PubMed 36456447 · DOI 10.1016/j.jcyt.2022.10.010